Blood Cholesteryl Ester Markers for Retinal Omega-3 Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring omega-3 polyunsaturated fatty acids in the retina are unreliable and imprecise, as they rely on dietary intake assessments or plasma lipid composition, which are complex and do not accurately reflect retinal levels due to non-linear relationships and regulatory factors.
Innovation Solution
A method using a mathematical model based on the quantification of specific cholesteryl esters, particularly cholesteryl 5,8,11,14,17-eicosapentaenoate, in a blood sample to predict the content of omega-3 polyunsaturated fatty acids in the retina, providing a more robust and reliable estimation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If dietary intake assessments or plasma lipid composition are used to measure omega-3 polyunsaturated fatty acids in the retina, then the measurement process is simplified, but the measurement precision and reliability deteriorate due to non-linear relationships and regulatory factors
Solution Approach 1:
The patent uses plasma cholesteryl esters as an intermediary biomarker to indirectly measure retinal omega-3 content. This mediator provides a reliable correlation between blood and retina omega-3 levels, solving the contradiction by maintaining measurement simplicity while improving accuracy through a validated biological intermediary that reflects actual retinal status
Solution Approach 2:
The invention shifts the measurement parameter from direct retinal biopsy (invasive, inaccurate) or dietary assessment (simple, unreliable) to plasma cholesteryl ester composition. This parameter change enables a blood-based test that is both operationally simple and scientifically accurate in predicting retinal omega-3 content
2Measurement precision
If retinal biopsy is performed to directly measure omega-3 polyunsaturated fatty acids, then measurement precision is improved, but the ease of operation deteriorates due to ethical constraints and procedural complexity
Solution Approach 1:
The patent employs plasma cholesteryl esters as a non-invasive intermediary that correlates with retinal omega-3 content. This mediator eliminates the need for ethical compromises of retinal biopsy while maintaining measurement reliability through established biological correlations between blood and retina lipid composition
Solution Approach 2:
The invention creates a blood-based copy or surrogate measure of retinal omega-3 status. By measuring cholesteryl esters in plasma that reflect retinal composition, the system obtains an accurate replica of retinal status without direct retinal sampling, resolving the contradiction between precision and ease of operation
3Measurement precision
If a comprehensive lipid profile analysis is performed to accurately assess omega-3 status, then measurement precision is improved, but the device complexity and cost increase
Solution Approach 1:
The patent extracts and focuses specifically on cholesteryl ester measurements from the complex plasma lipid profile. By isolating this particular lipid fraction that correlates with retinal omega-3 content, the system achieves accurate assessment without requiring comprehensive analysis of all plasma lipids, thereby reducing device complexity while maintaining precision
Data Source
AI summary
The present invention relates to a method for determining the content of omega-3 polyunsaturated fatty acids in the retina of a subject comprising the determination of the content of at least one cholesteryl ester in a blood sample from said subject, the content of omega-3 polyunsaturated fatty acids in the retina being correlated to the content of said at least one cholesteryl ester, said at least one cholesteryl ester being cholesteryl 5,8,11,14,17-eicosapentaenoate.